The first accurate portable and easy to manage pulse oximeter located on the us...
The first accurate portable and easy to manage pulse oximeter located on the user s mobile for the prevention and monitoring of COPD disease
Chronic Obstructive pulmonary Disease (COPD) is the fourth leading cause of death globally. This disease is characterized by persistent respiratory symptoms and airflow limitation. To date, more than 210 millions people suffer COP...
ver más
I4LIFE INNOVACION Y DESARROLLOS
Cnae: 7219. en aquellas actividades que tuvieran carácter profesional la sociedad actuará como medidadora o intermediaria. objeto: 1-la inve...
TRL
4-5
| 80K€
Fecha límite participación
Sin fecha límite de participación.
Financiación
concedida
El organismo H2020 notifico la concesión del proyecto
el día 2019-08-31
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
PTQ-08-01-06894
DESARROLLO DE UN SISTEMA INALÁMBRICO VERSÁTIL, PARA LA MONIT...
45K€
Cerrado
PID2021-126455OB-I00
ECOSISTEMA DE SALUD INTELIGENTE PARA EL MANEJO DE ENFERMEDAD...
176K€
Cerrado
V-LAP
A revolutionary direct daily heart monitoring platform for...
3M€
Cerrado
MONILET
Monitoring Bracelet for Health Use
71K€
Cerrado
PTQ2023-013156
Nuevas herramientas biosensoras para el diagnóstico remoto,...
109K€
Cerrado
PTQ2021-012005
Nuevas herramientas biosensoras para el diagnóstico remoto,...
100K€
Cerrado
Información proyecto i4case
Duración del proyecto: 4 meses
Fecha Inicio: 2019-04-24
Fecha Fin: 2019-08-31
Líder del proyecto
I4LIFE INNOVACION Y DESARROLLOS
Cnae: 7219. en aquellas actividades que tuvieran carácter profesional la sociedad actuará como medidadora o intermediaria. objeto: 1-la inve...
TRL
4-5
| 80K€
Presupuesto del proyecto
71K€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
Chronic Obstructive pulmonary Disease (COPD) is the fourth leading cause of death globally. This disease is characterized by persistent respiratory symptoms and airflow limitation. To date, more than 210 millions people suffer COPD with crisis respiratory episodes (exacerbation), 1 to 3 times per year. The easiest way to prevent COPD exacerbations is measuring the oxygen level in blood. Therefore, COPD patients and their families or caregivers need devices for continuous monitoring of oxygen saturation. I4case solves these problems being an innovative smart solution integrated by a small and easy-to-manage pulse oximeter, as well as a smart data processing platform. I4case is located on the user´s mobile, goes with the patients everywhere, and is connected to the physicians who will have a 24h follow-up of their patients. I4case will reduce the 70% of the COPD respiratory crisis, achieving COPD direct and indirect costs savings of 40% (€58.4B just in Europe).
Currently, i4life is following a B2C approach and is targeting the global pulse oximeter market, which is experienced a huge growing, reaching €2B by 2021 (CAGR 6.5%). i4life customers will be COPD patients, their families, and caregivers, focusing at the first stage in old people. More than €18M sales projection has been estimated for the third year of commercialization. I4life will expand after the achievement of CE Medical Device approval. Furthermore, with clinical partners such as SEPAR Spanish society of pulmonology and thoracic surgery or the University of Oviedo, i4life is equipped to start full-scale clinical studies.